Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Jubilant Pharmova Ltd’s stock declined sharply to a fresh 52-week low of Rs.783.75 on 10 Mar 2026, marking a significant downturn amid broader market volatility and company-specific headwinds. The stock underperformed its sector and broader indices, reflecting ongoing concerns about its financial performance and valuation metrics.

Jubilant Pharmova Ltd’s stock declined to a fresh 52-week low of Rs.786.55 on 9 Mar 2026, marking a significant drop amid broader market weakness and company-specific performance concerns. The stock has been under pressure for the past two sessions, reflecting a cumulative fall of 3.31% during this period.

Jubilant Pharmova Ltd’s shares declined to a fresh 52-week low of Rs.819 today, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures on its financial metrics and valuation.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Jubilant Pharmova Ltd’s stock price declined sharply to a new 52-week low of Rs.820.05 on 2 March 2026, marking a significant milestone in its recent downward trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Jubilant Pharmova Ltd commenced trading today with a pronounced gap down, opening at a price 5.34% lower than its previous close, reflecting heightened market apprehension. The stock hit a fresh 52-week low of Rs. 820.05 amid continued downward momentum, underperforming its sector and broader indices.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date analysis of the company’s standing.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Jubilant Pharmova Ltd has reported a marked deterioration in its financial performance for the quarter ended December 2025, with key metrics signalling a shift from prior stability to negative trends. Despite achieving record net sales, the company’s profitability and margin indicators have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Jubilant Pharmova Ltd. reported a sharp 53.53% quarter-on-quarter decline in consolidated net profit for Q3 FY26, falling to ₹55.90 crores from ₹120.30 crores in the previous quarter, even as revenue reached an all-time high of ₹2,122.50 crores. The pharmaceutical manufacturer's shares tumbled 4.22% following the results announcement, closing at ₹933.40 on February 06, 2026, as investors reacted negatively to deteriorating profitability metrics and compressed margins across the board.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Jubilant Pharmova Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The company’s shares have declined sharply in recent weeks, underperforming the broader market and prompting a downgrade in its technical rating to a Sell, reflecting growing investor caution.

Jubilant Pharmova Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.